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1. Introduction 
Facing the demand of obtaining the best cost-efficacy treatments, we are always searching 
for new alternatives to the existing therapies. The incorporation of new diagnostic 
techniques and screening, along with the continued development of safer and more effective 
drugs has improved considerably the expectations and the quality of life of patients. 
Still, there is no ideal solution to many of the diseases faced by health professionals in daily 
clinical practice, so we still have to look for alternatives to the established treatments. The 
idea of a targeted and personalized therapy to achieve therapeutic success is a goal that is 
getting more and more important every day. In this context there arises the concept of 
personalized medicine which is related in our case to the genetic variability associated with 
different individual response to the same treatment. That is, there is a difference in the 
response to the same drug in different patients that appears to be related to the different 
versions of each patient's genes coding for transport proteins, for enzymes involved in 
metabolism and those genes responsible for the drug mechanism of action, all necessary for 
the drug to perform its therapeutic effect. This kind of research is developed by two 
disciplines: pharmacogenetics and pharmacogenomics. These two terms are often mixed 
and difficult to distinguish, so the international regulatory organizations have tried to fix the 
proper definitions of both terms. The European Medicines Agency shows the definitions on 
its web site (www.ema.europa.eu, EMEA/CHMP/ICH/437986/2006) where according to 
the the International Conference on Harmonisation (ICH), Pharmacogenomics is defined as 
the study of variations of DNA and RNA characteristics as related to drug response, while 
Pharmacogenetics is a subset of pharmacogenomics and is defined as the study of variations 
in DNA sequence as related to drug response.  
So, in practice Pharmacogenetics studies the influence of genetic factors in transport, 
metabolism and drug action. The examples of pharmacogenetic tests employed in the 
clinical practice are increasing day by day, as for instance when establishing first treatment 
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in HIV patients, before employing Cetuximab in colorectal cancer and before Warfarin 
treatment. In these cases, where it has been demonstrated that it exists a correlation 
between some known genetic variants and low or no response to treatment, or even 
occurrence of adverse effects, the clinician needs the genetic test tool in order to settle the 
correct therapy to each patient. The increase of this genetic testing need is reflected also by 
the United States Food and Drug Administration (FDA) that publishes on its web site the 
list containing those drugs with a genetic test, recommended or compulsory, in their drug 
label. Table 1 shows some examples of drugs with pharmacogenomic/genetic marker 
published in FDA website. 
 
Pharmacogenetic Biomarkers in Drug Labels 
 Theraputic Area Biomarker   Label Sections   
Aripiprazole  Psychiatry  CYP2D6  Clinical Pharmacology  
Azathioprine Rheumatology  TPMT  
Dosage and Administration, 
Warnings and Precautions, 
Drug Interactions, Adverse 
Reactions, Clinical 
Pharmacology  
Carvedilol Cardiovascular  CYP2D6  
Drug Interactions, Clinical 
Pharmacology  
Celecoxib Analgesics  CYP2C9  
Dosage and Administration, 
Drug Interactions, Use in 
Specific Populations, 
Clinical Pharmacology  
Cetuximab Oncology  EGFR  
Indications and Usage, 
Warnings and Precautions, 
Description, Clinical 
Pharmacology, Clinical 
Studies  
Cetuximab  Oncology  KRAS  
Indications and Usage, 
Clinical Pharmacology, 
Clinical Studies  
Maraviroc Antivirals  CCR5  
Indications and Usage, 
Warnings and Precautions, 
Clinical Pharmacology, 
Clinical Studies, Patient 
Counseling Information  
Table 1. Examples of pharmacogenetic biomarkers in drug labels in FDA website 
(www.fda.gov, accession date: (24/06/2011). 
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On the other hand, Pharmacogenomics is responsible for discovering the relationships 
between genes and disease by means of the molecular etiology and pathways of each illness. 
The identification of these new associations opens a window to search for new drugs for 
novel therapeutic targets. 
The aim of both disciplines is to obtain the highest therapeutic effect with the lowest risk, 
minimizing the adverse effects of the treatments. This should lead to a better control of the 
disease through personalized medicine. 
In order to start explaining the main findings of Pharmacogenetics in the renal 
transplantation field, we need first to understand some basic concepts. The first one is 
Polymorphism, which is a monogenic mendelian character that is normally present in the 
population at least in 1% frequency. It is characterized by the presence of more than one 
allele in a same gene locus, and consequently, more than one phenotype. The 
polymorphisms that have a meaning in pharmacogenetics are those who represent different 
alleles in a gene related to the interaction of a drug with the organism. There are different 
types of polymorphisms: those were the change from one allele to the variant is only one 
nucleotide are called SNPs, Single Nucleotide Polymorphisms, and these will be the subject 
of most part of the research in the field, including our own work. But there are also other 
kind of polymorphisms as RFLPs, Restriction Fragment Lenght Polymorphisms, and VNTR, 
Variable Number Tandem Repeats. SNPs are the most common ones, representing 90% of 
the whole genetic variability. It is important not to mix this concept up with the term 
“mutation”, although actually they are sometimes mixed. A mutation is usually less 
frequent than a polymorphism, being present in less than 1% of the population but also a 
mutation represents a very little part of the whole genetic variability and is mostly 
associated with the pathology concept: a mutation is most always the cause of a 
missfunction or disease, while a polymorphism will only show some biological effect under 
some concrete circumstances. For instance, if we are carriers of a variant in a polymorphic 
site, related to a better efficacy of a given drug, we will only notice this effect if we take that 
drug, but if we never take it, we will probably not find any biological effect in our body due 
to carrying that variant.  
Another important concept to consider is the Haplotype. We refer to haplotype when we 
talk about alleles which tend to be inherited together because they are close to each other 
on the chromosomes. The haplotypes have been extensively studied by the HapMap 
project (www.hapmap.org). Currently, the investigations are more and more directed to 
the study of the effect of several combined SNPs, instead of aisled SNPs, especially those 
that form an haplotype. The reason for this is that most probably the biological effects that 
we could find are the result of the sum of the effect of several SNPs in different genes 
affecting several parts of the pathway of the drug. Moreover, the effect of a single SNP 
can be, in turn, enhanced, reduced or silenced by compensation by the effect of other 
SNPs. Related to the term haplotype we can also hear about Linkage Disequilibrium, LD, 
which is the occurrence of some combinations of alleles or genetic markers in a population 
more often or less often than would be expected from a random formation of haplotypes 
from alleles based on their frequencies. This aspect is also important in the study of SNPs, 
since in many cases, a SNP that apparently seems to have no clear biological meaning may 
be in disequilibrium with another SNP with a known effect and taking this into account, 
this property could help us infer the genotype of a patient in several SNPs, by only 
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studying one or two of them if they are linked, and also it makes sense to study not only 
the SNPs with a clear direct effect, but those apparently non-functional but linked to the 
functional ones. 
The application of these skills and expertise in the field of transplantation could be one of 
the great advances in current immunosupressive therapy. In the transplantation field, there 
are still many unanswered questions, its success depends on the fragile equilibrium between 
the risks and benefits of immunosuppression. Therapeutic drug monitoring helps to 
determine suitable immunosuppressant dose adjustments but usually the work is done by 
assay-error method so the challenge now is to combine pharmacokinetic with 
pharmacogenetic information to provide patients with the most suitable treatment. Many 
papers have been written about genetic variability based on SNPs influencing 
immunosuppressant blood levels but the results are still contradictory in many cases, 
probably due to the hidden effects of other SNPs not included in the study, the number of 
patients included, their ethnicity (SNP frequencies can be very different from one ethnicity 
to another) and so on. 
Just focusing our review of the state of the art in tacrolimus and cyclosporine, two genes 
seem to be the most relevant on having pharmacogentic effects on these drugs: the ABCB1 
gene, coding for the transporter P-glycoprotein, and the CYP3A5 gene, coding for an 
extensive drug-metabolizing enzyme of cytochrome P450 family. 
Tacrolimus and cyclosporine are calcineurin inhibitors indicated for prophylaxis of renal, 
liver and heart transplant rejection. Cyclosporine has a broader use as immunosuppressive 
agent, as apart from preventing transplant rejection (kidney, liver, heart, lung and bone 
marrow) it is also employed in autoimmune diseases (uveitis endogenous, psoriasis, 
nephrotic syndrome, rheumatoid arthritis and atopic dermatitis). In the metabolism of both 
drugs, cytochrome P-450 plays an important role, specifically the CYP3A5 isoform, but also 
CYP3A4 in the case of cyclosporine. On the other hand, they are both transported out of 
cells by P-glycoprotein, encoded by the gene ABCB1. Changes in expression or function of 
these proteins will cause changes in the absorption, metabolism and distribution of both 
drugs and, therefore, can lead to changes in the response and toxicity of the treatment. The 
characterization of genetic variants, as for instance SNPs, that cause variations in expression 
or function can help in establishing effective doses and in minimizing adverse reactions 
(Astellas Pharma, S.A., 2010; Staatz et al., 2010).  
The good correlation between these two drugs blood levels and their tissue concentration, 
makes them suitable for pharmacokinetic monitoring to prevent graft rejection or toxicity. If 
we add the inter- and intra-individual variability, a narrow therapeutic range and a clear 
correlation between high blood levels and appearance of toxicity, then we have two perfect 
candidates for the need of dose optimization. Other factors affecting tacrolimus and 
cyclosporine dosage/concentration after renal transplantation are consistent with the 
features of the patients (renal and hepatic function, age, race). Liver function, albumin, 
hematocrit, gastrointestinal disturbances and the effects of food are also important factors 
responsible for the variation of dosage/concentrations (Marqués et al., 2009). 
The final goal of pharmacogenetics in transplantation is to find a clear link between genetic 
variations and pharmacokinetics/pharmacodynamics of the drugs employed, to allow us to 
find the optimal doses of both initial and maintenance periods, ensuring the success of the 
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graft and reducing treatment toxicity. Amongst all the SNPs described in the literature 
included in genes related to these drugs, we need to validate those that really have an 
impact on actual clinical practice, those that really alter drug levels/efficacy/toxicity and we 
can only achieve that through research, in order to obtain individualized therapies as 
effective as possible. Contradictory results in the published studies seem to tarnish the 
utility of pharmacogenetics, but there are also many encouraging works, where clear 
correlations are found. Probably a good experimental design, without alteration of the real 
clinical setting could help to discriminate whether these studies will be useful or not in the 
therapeutic decisions, but certainly we need multiple approaches correlating genetics with 
kinetics and with safety/efficacy; good and accurate informatic tools to process such a great 
quantity of information; and finally, we do not have to forget other important factors 
involving the patient as concomitant drugs and donor genotype. In this chapter we are 
presenting a summary of some relevant published works and some of our own group's 
results in this area. 
2. Tacrolimus 
2.1 Absorption 
Tacrolimus has a mean oral bioavailability ranging from 20 to 25%. After oral 
administration, peak concentrations (Cmax) are reached in an interval of 1 to 3 hours. Co-
administration with food leads to a decrease in the speed and extent of absorption, being 
more accentuated in the case of fat rich food. Once in blood, it is highly found bound to 
erythrocytes and plasma proteins (> 98.8%), with preference for serum albumin and α-1 acid 
glycoprotein (Astellas Pharma, S.A., 2010). 
2.2 Distribution 
It is widely distributed throughout the body reaching a volume of distribution around 1,300 
liters. It has a low clearance that, as with its half-life, differs depending on the type of 
transplantation performed and the age of the patients (total clearance in pediatric patients 
undergoing liver transplantation is twice that of adult patients with the same 
transplantation type). Generally, it has a long half-life that is affected by variations in 
clearance rates observed in transplantation patients (Astellas Pharma, S.A., 2010). 
2.3 Metabolism 
Tacrolimus is extensively metabolized in the liver but also has a minimal metabolism in the 
intestine. The primary responsible is the cytochrome P450. Several products of metabolism 
have been identified, but there is only one metabolite with immunosuppressive activity 
similar to that of tacrolimus, however, it does not contribute to the pharmacological activity, 
since it has not been detected in systemic circulation (Astellas Pharma, S.A., 2010). 
2.4 Elimination 
The main route of elimination of tacrolimus is the faeces. Only 2% is excreted in urine. Only 
1% of the administered tacrolimus appears unchanged in feces and urine (Astellas Pharma, 
S.A., 2010). 
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3. Cyclosporine 
3.1 Absorption 
The new current formulation of cyclosporine microemulsion compared to conventional 
forms, has a faster absorption, leading to a reduction of 1 hour in the t max and Cmax 
increased by 59%, with an increase of 29% in AUC (Novartis Farmacéutica, S.A., 2010). 
3.2 Distribution 
Most of the cyclosporine is outside the blood compartment. In the blood it is preferently 
distributed in plasma (33 - 47%) and erythrocytes (41-58%). 90% is fixed to plasma proteins, 
primarily lipoproteins (Novartis Farmacéutica, S.A., 2010). 
3.3 Metabolism 
Biotransformation of cyclosporin is broad and leads to the formation of about 15 
metabolites. There is not a main metabolic pathway and it suffers enterohepatic cycle 
(Novartis Farmacéutica, S.A., 2010). 
3.4 Elimination 
It is mainly performed via the bile. Only 6% of the oral dose is excreted in the urine (0.1% as 
unchanged drug) (Novartis Farmacéutica, S.A., 2010). 
4. Genetic polymorphisms 
A great number of genes are thought to be involved in different effects of 
immunosuppressive therapy (www.fda.gov; www. pharmgkb.org). Two genes in particular 
have demonstrated clear correlations in several studies: ABCB1 (or MDR1), which codes for 
the transporter P-glycoprotein and CYP3A5, which codes for an extensive drug 
metabolizing enzyme of the cytochrome P450 family. 
4.1 ABCB1 genetic polymorphisms 
P-glycoprotein is encoded by the multidrug resistance gene (MDR1), also known as the 
ABCB1 gene. The protein encoded by this gene is an ATP-dependent drug efflux pump for 
xenobiotic compounds with broad substrate specificity. It is responsible for decreased drug 
accumulation in multidrug-resistant cells and often mediates the development of resistance 
to anticancer drugs. This protein also functions as a transporter in the blood-brain barrier. 
ABCB1 is polymorphically expressed, with at least 50 SNPs identified to date 
(http://www.ncbi.nlm.nih.gov). 
4.1.1 Influence on tacrolimus pharmacokinetics. 
The results of the influence of ABCB1 on the pharmacokinetics of tacrolimus are 
controversial. Some studies talk about an increase in the ratio Co/dose and lower dose 
requirement in those individuals expressing variant ABCB1 3435 TT regarding the CC 
variant, related to a possible lower functional activity of P-glycoprotein in the carriers of TT 
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variant (Staatz et al, 2010). This “3435 C>T” is the common nomenclature for the SNP 
cataloged as rs1045642 in the SNP database of NCBI website (http://www.ncbi.nlm. nih.gov), 
where C is the ancestral allele (also “wild type”) and most frequent and T the less frequent one 
and they lead to three different genotypes: CC, CT and TT. In contrast, some other studies 
have failed to find an association between the ABCB1 3435C>T and changes in tacrolimus 
blood levels. In a prospective study with 96 renal transplant recipients, the effect of genetic 
polymorphisms of ABCB1 on tacrolimus whole blood levels was analyzed, concluding that 
ABCB1 1199G>A, 3435C>T and 2677G>T/A SNPs (rs2229109, 1045642, 2032582, respectively), 
appeared to reduce the activity of P-glycoprotein towards tacrolimus, increasing tacrolimus 
peripheral blood mononuclear cell concentrations. Nevertheless, the impact of ABCB1 genetic 
polymorphisms on tacrolimus blood concentrations was negligible (Capron et al., 2010). In 
another study on Chinese renal transplant recipients, MDR1 3435C>T polymorphism was not 
an important factor in tacrolimus pharmacokinetics (Rong et al., 2010). In a retrospective study 
of 81 renal transplant recipients the effect on tacrolimus dosages and concentration/dose ratio 
of four frequent MDR1 SNP possibly associated with P-gp function (T-129C in exon 1b, 
1236C>T in exon 12, 2677G>T,A in exon 21, and 3435C>T in exon 26; corresponding to 
rs3213619, 1128503, 2032582 and 1045642, respectively). In the general caucasian population, 
the SNP in exons 12, 21, and 26 exhibited incomplete linkage disequilibrium, which means that 
the different variants of each SNP tend to be displayed together, but not in the 100% of the  
 
Fig. 1. Influence of the functional activity of glycoprotein-P (transporter in apical membrane) in 
the transport of tacrolimus (stars) in the intestine epithelium. The diagram shows the different 
degree of drug absorption due to variations in ABCB1/MDR1 polymorphic site rs1045642. 
Individuals with TT variant have a decreased transporter activity and hence greater absorption 
efficiency. CC variant causes more expulsion out of the cell, which decreases absorption. 
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individuals. One month after tacrolimus introduction, exon 21 SNP correlated significantly 
with the daily tacrolimus dose (P < or = 0.05) and the concentration/dose ratio (P < or = 
0.02). Tacrolimus dose requirements were 40% higher in homozygous TT than in wild-type 
patients GG for this SNP. The concentration/dose ratio was 36% lower in the wild-type GG 
patients, suggesting that, for a given dose, their tacrolimus blood concentration is lower. 
Haplotype analysis substained these results and suggested that exons 26 and 21 SNPs may 
be associated with tacrolimus dose requirements (Anglicheau et al., 2003). 
4.1.2 Influence on cyclosporine pharmacokinetics 
Nowadays the data about ABCB1 influence on cyclosporine pharmacokinetics are not 
conclusive, either. Many studies have tried to find correlations with ABCB1 SNPs 3434C>T, 
2677G>T/A and 1236C>T without significant findings. A recent meta-analysis that included 
1036 renal transplantation recipients, concluded that there were no significant differences in 
the influence of ABCB1 3435C>T on cyclosporine pharmacokinetics (AUC4/Dose, CL/F, 
Cmax/Dose or C0/Dose). However, it was indicated in this meta-analysis that CC carriers 
had lower cyclosporine exposure presented as AUC 0–12 than those with at least one T 
allele (CT or TT). In a recent study that included 225 renal transplant recipients treated with 
cyclosporine, ABCB1 2677G>T SNP correlated significantly with dose-adjusted levels in 
patients, at 1, 3 and 6 months after renal transplantation. Recipients with the wild-type 
genotype of this SNP were associated with significantly lower dose-adjusted values and 
consequently required higher cyclosporine daily dose to attain the therapeutic level. ABCB1 
1236C>T also had a minor influence on dose-adjusted C2/T0 levels (Singh et al, 2010). 
4.2 CYP450 genetic polymorphisms 
The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved 
in drug metabolism and synthesis of cholesterol, steroids and other lipids. This proteins are 
localized in the endoplasmic reticulum and their expression is induced by glucocorticoids 
and some pharmacological agents (http://www.ncbi.nlm.nih.gov). 
CYP3A5 is found in the liver, small intestine and kidney. One of the most relevants SNPs in 
this gene is rs776746, also know as 6986 A>G, being G the most frequent allele. Allele *3 is 
the wild type genotype, GG, while *1 is the variant homozygous AA and heterozygote A/G 
is known as *1/*3. There are clear ethnic differences in the prevalence of the CYP3A5*3 
genotype. At the molecular level, the SNP is located in intron 3, and the change of base 
produces a splicing defect. The result is a nonfunctional protein (allele *3). The patients that 
show the allelic variant *3 in homozygosis G/G, also called non-expressors, are slow 
metabolizers of the immunosuppressant. In contrast, heterozygote A/G alleles *1/*3 are 
intermediate metabolizers, whereas those carriers of allele *1 in homozygosis A/A are 
normal metabolizers (Glowacki et al, 2011; Macphee et al, 2005; www.pharmgkb.org) 
4.2.1 Influence on tacrolimus pharmacokinetics 
CYP3A5 may play a more important role than CYP3A4 in the metabolism of tacrolimus in 
individuals who are CYP3A5 expressors, so we will focus on this enzyme. The intrinsic 
clearance of tacrolimus is approximately 2-fold higher for CYP3A5 than for CYP3A4 
(Hesselink et al., 2008). This plasmatic clearance is higher in those individuals with genotype 
CYP3A5*1/*3 regarding those CYP3A5*3/*3 (Haufroid et al., 2006). In fact, CYP3A5*1 is 
www.intechopen.com
 
Pharmacogenetics of Immunosuppressive Drugs in Renal Transplantation 
 
151 
responsible from about 60% of tacrolimus hepatic metabolism (Dai et al., 2006; Thervet et al., 
2010), so it is of great interest studying it in order to establish optimal doses that reach 
quickly the efficient blood concentrations, avoiding toxicity but also assuring the necessary 
concentrations to avoid rejection. The studies performed so far indicate the need to 
administrate higher tacrolimus doses in patients CYP3A5*1/*1. In fact, in some of those 
studies there is even a recommendation of an initial double dose for those patients (Haufroid 
et al, 2006). In a study with forty kidney recipients, CYP3A5*1 variant was associated with 
significant lower tacrolimus dose adjusted concentration at 3, 6, 12 and 36 months after 
transplantation, concluding that CYP3A5*1 carriers need higher tacrolimus dose than 
CYP3A5*3 homozygotes to achieve the target blood concentration (Katsakiori et al., 2010). 
Similarly, in a study with 28 chinese renal transplant recipients, the patients with *1/*3 
showed significantly lower tacrolimus blood levels than those with the *3/*3 in the first and 
second week after transplantation (Zhang et al., 2010). In another similar study, on Chinese 
renal transplant recipients, individuals who were CYP3A5*1 carriers required a higher dose 
of tacrolimus than CYP3A5*3/*3, indicating a significantly lower dose-adjusted AUC(0-12) of 
tacrolimus (Rong et al., 2010). The last reviewed work, with 200 patients objectifies that 
patients who were CYP3A5*3/*3 received significantly higher tacrolimus dose at 1 week, 6 
months, and 1 year (Tavira et al., 2011). Some studies found that the weighted mean apparent 
oral clearance was 48% lower in CYP3A5 nonexpressors than CYP3A5 expressors (range, 
26%-65%) (Barry & Levine, 2010). Recently, a study with 280 transplant recipients concludes 
that patients receiving a pharmacogenetic adaption of the daily dose of tacrolimus were 
associated with improved achievement of the target C0 (Thervet et al, 2010). 
4.2.2 Influence on cyclosporine pharmacokinetics 
Unlike tacrolimus, CYP3A4 may play a more dominant role than CYP3A5 in the metabolism 
of cyclosporine. The intrinsic clearance of cyclosporine, calculated from total metabolite 
formation, is approximately 2.3-fold higher for CYP3A4 than for CYP3A5 (Dai et al., 2006). 
Still, the results of studies conducted so far do not indicate a clear relationship (Anglicheau 
et al., 2007) with 3A4 isoform. However, many papers continue studying the effect of both 
on the metabolism of cyclosporine. A recent meta-analysis with twelve studies includes the 
effects of CYP3A5 during cyclosporine dose adjustment. This meta-analysis showed that 
CYP3A5*3/*3 polymorphism is associated with cyclosporine dose-adjusted concentration 
(dose-adjusted trough and dose-adjusted peak concentrations) in renal transplant recipients 
and patients carrying the CYP3A5*3/*3 genotype will require a lower dose of cyclosporine 
to reach targets levels compared with the CYP3A5*1/*1 or 1*/*3 carriers (Zhu et al., 2011). 
5. Our results 
5.1 Objective 
The aim of our studies was to evaluate the effect of the most relevant SNPs in ABCB1 and 
CYP3A5 genes, in renal transplant recipients and their donors, regarding blood 
concentrations of tacrolimus in the first two weeks post-transplantation. 
5.2 Materials and methods 
One blood sample, collected in anticoagulation tubes at routine extraction, was obtained in 
each of 97 renal transplant recipients and their donors (caucasians). The DNA was extracted  
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from 200 µL of blood using a commercially available kit based on centrifugation in 
microcolumns (UltraClean BloodSpin DNA Isolation Kit; MoBioLaboratories, Inc, Carlsbad, 
California). After quantification using a spectrophotometer (NanoDrop Technologies Inc, 
Wilmington, Delaware) to determine the concentration and purity, DNA was stored at -20°C 
until use. A genetic analysis platform (MassARRAY; Sequenom, Inc, San Diego, California) 
was used to obtain the genotypes of each sample in the SNPs rs1045642 (3435C>T), 
rs2032582 (2677G>T/A), and rs1128503 (1236C>T) of the ABCB1 gene, and in the SNPs 
rs776746 (6986A>G, CYP3A5*3) and rs10264272 (267871G>A, CYP3A5*6) of the CYP3A5 
gene. All the 97 patients received tacrolimus as the primary immunosuppression drug, at an 
initial dose of 0.2 to 0.3 mg/kg/24 h. Blood concentration of tacrolimus was measured 
routinely using a clinical chemistry system (Dimension; Siemens Healthcare, Deerfield, 
Illinois) to determine the trough level (C0 , in nanograms per milliliter). Drug blood 
concentrations from the first and second weeks were determined, and all of the measured 
levels in the patients during that period were considered. The resulting values were plotted 
in the form of median and quartile range, 1 for each week in each group of recipients or 
recipient with their donors, according to genotypes. Normality tests of Kolmogorov-Smirnof 
and Shapiro-Wilk were performed and then differences between groups were evaluated 
using the Mann-Whitney test (nonparametric test that compares two groups) 
5.3 Results 
The SNP genotyping of the 167 samples showed similar frequencies to those expected for 
Caucasian population in public databases (SNP Database in NCBI site). Tables 2 to 4 show 
the relationship between the frequencies observed in recipients in our study regarding the 
expected ones according to the data from public data bases of the ABCB1 and CYP3A5 
genes, in the most relevant genotyping assays in caucasian population. Tables 5 to 7 show 
the same information but regarding the donors of the transplanted kidneys. The data related 
to donors is a little bit outside the expected range, while there is a better fit in recipient's 
data. We associate these findings to the lower number of donors, thus we can appreciate 
that in recipients, having a larger number of samples, the frequencies fit better. 
GENE POLYMORFISMS
EXPECTED FREQUENCY (%) FOUND FREQUENCY (%) 
CC CT TT CC CT TT 
ABCB1 rs 1045642 12.5-15.5 50-60.3 37.5-24.1 22.68 52.28 24.74 
 rs 1128503 32 41 27 34.02 46.39 24.05 
Table 2. Recipients' genotypes frequency regarding the expected frequencies from public 
data bases. 
GENE POLYMORFISMS
EXPECTED FREQUENCY (%) FOUND FREQUENCY (%) 
AA AG GG GT TT AA AG GG GT TT 
ABCB1 rs 2032582 0 0 32.3-
32.2
48.4-
55.9
19.3-
11.9
1.03 1.03 32.99 50.52 14.43 
Table 3. Recipients' genotypes frequency regarding the expected frequencies from public 
data bases. 
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GENE POLYMORFISMS
EXPECTED FREQUENCY (%) FOUND FREQUENCY (%) 
GG GA GG GA 
CYP3A5 rs 776746 88.3-95.5 11.7-4.5 81.44 18.55 
rs 1026427 100 0 97.94 2.06 
Table 4. Recipients' genotypes frequency regarding the expected frequencies from public 
data bases. 
GENE 
POLYMORFISM
S 
EXPECTED FREQUENCY (%) FOUND FREQUENCY (%) 
CC CT TT CC CT TT 
ABCB1 rs 1045642 12.5-15.5 50-60.3 37.5-24.1 30.07 49.18 14.75 
 rs 1128503 32 41 27 39.06 50 9.38 
Table 5. Donors' genotypes frequency regarding the expected frequencies from public data 
bases. 
GENE POLYMORFISMS
EXPECTED FREQUENCY (%) FOUND FREQUENCY (%) 
AA AG GG GT TT AA AG GG GT TT 
ABCB1 rs 2032582 0 0 32.3-
32.2
48.4-
55.9
19.3-
11.9
0 0 42.37 54.24 3.39 
Table 6. Donors' genotypes frequency regarding the expected frequencies from public data 
bases. 
GENE POLYMORFISMS
EXPECTED FREQUENCY (%) FOUND FREQUENCY (%) 
GG GA GG GA 
CYP3A5 rs 776746 88.6-95.5 11.4-4.5 79.10 19.4 
rs 1026427 99 1 98.5 1.43 
Table 7. Donors' genotypes frequency regarding the expected frequencies from public data 
bases. 
5.3.1 ABCB1 
According to the literature, rs1045642 seems to be the most relevant SNP in ABCB1 gene 
regarding its correlation with tacrolimus or cyclosporine blood levels. 
Figure 2 shows tacrolimus levels as trough concentration, corrected by administered dose 
and weight of the patient (C0/Dc= C0/(Dose/weight)) during the first two weeks after renal 
transplantation, grouped in a way that we represent the data of those recipients whose 
donor has the same genotype as them (eg. CC/CC, means recipients CC whose donors were 
also CC). The data are represented as median inside the whole data range, remarking the 
interquartilic range which includes the 50% of the data. The statistical test applycated was 
Mann-Whitney two-tailed test. Statistically significant differences (p<0,05) were found 
between CC/CC vs TT/TT and also between CT/CT vs TT/TT in the second week after 
transplantation. With this kind of analysis we evaluate the global effect of the variant, C or 
T, without taking into account if the effect is greater in recipients or in donors. 
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Fig. 2. Tacrolimus corrected trough concentration in renal recipients regarding single 
nucleotide polymorphism (SNP) rs1045642 genotype recipient/donor. Corrected trough 
concentration (C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding the 
patient and donor genotype, grouped so that both genotypes match, in SNP rs1045642 of 
ABCB1 gene, in the first (1w) and second week (2w) after transplantation. The horizontal 
line inside each bar is the median of the data, the bar is the interquartilic range, including 
50% of the data, and the lines up and down the bars cover the whole data range for each set. 
A significant difference (*= p<0,05)was achieved in the second week between CC/CC and 
TT/TT, and also between CT/CT and TT/TT employing Mann-Whitney two-tailed test. 
Figures 3, 4 and 5 show the same kind of analysis as in Figure 2 but with patients grouped 
by a single recipient variant comparing the three possible donors’ genotype.  
We could not find any statistically significant differences in Fig.3, applying Mann-Whitney 
non-parametric test, most probably because we only had one value for CC/TT in the first 
week, and two for the second. However, those three values show the expected trend of 
higher tacrolimus levels than the rest of the groups. 
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Fig. 3. Tacrolimus corrected trough concentration in renal recipients regarding single 
nucleotide polymorphism (SNP) rs1045642 in CC recipients. Corrected trough concentration 
(C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding the patient and 
donor genotype, showing the data from recipients CC divided in three different groups 
according to their donor genotype (recipient/donor), in the first (1w) and second week (2w) 
after transplantation. The horizontal line inside each bar is the median of the data, the bar is 
the interquartilic range, including 50% of the data, and the lines up and down the bars cover 
the whole data range for each set. No significant differences were found. 
 
Fig. 4. Tacrolimus corrected trough concentration in renal recipients regarding single 
nucleotide polymorphism (SNP) rs1045642 in CT recipients. Corrected trough concentration 
(C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding the patient and 
donor genotype, showing the data from recipients CT divided in three different groups 
according to their donor genotype (recipient/donor), in the first (1w) and second week (2w) 
after transplantation. The horizontal line inside each bar is the median of the data, the bar is 
the interquartilic range, including 50% of the data, and the lines up and down the bars cover 
the whole data range for each set. Significant differences were found between CT/CC and 
CT/TT at week two (p<0,05) employing Mann-Whitney two-tailed test. 
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Fig. 5. Tacrolimus corrected trough concentration in renal recipients regarding single 
nucleotide polymorphism (SNP) rs1045642 in TT recipients. Corrected trough concentration 
(C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding the patient and 
donor genotype, showing the data from recipients TT divided in three different groups 
according to their donor genotype (recipient/donor), in the first (1w) and second week (2w) 
after transplantation. The horizontal line inside each bar is the median of the data, the bar is 
the interquartilic range, including 50% of the data, and the lines up and down the bars cover 
the whole data range for each set. Significant differences were found between TT/CC and 
TT/TT at week two (p<0,05) employing Mann-Whitney one-tailed test. 
There is a clear trend of CC genotype in SNP rs1045642 to normalize tacrolimus levels, while 
there is always an increase related with T allele, especially in TT genotype, where most of 
the times, statistically significant differences are reached at week two post-transplantation. 
With these data, we can calculate an increase in the value of the median up to 286.53% when 
comparing the difference between the median in group CC/TT and the median in group 
CC/CC (fig. 2, second week) Table 8 shows the differences in percentage of the medians 
from figures 2, 3, 4 and 5, and also the quantity of recipients and tacrolimus level values 
included in each of the figures. 
But we have not only studied rs1045642, also two other relevant SNPs in ABCB1 that have 
been described to be in linkage disequilibrium with the first: rs1128503 and rs2032582. With 
the genotype data for these three SNPs in our renal transplantation recipients, we constructed 
haplotype groups, being “Normal” those recipients carrying CC in rs1045642, CC in rs1128503 
and GG in rs2032582, and “Variant” those carrying the rest of the possible combinations, 
containing at least one T allele in any of the three SNPs. The results correlating these genotypes 
with tacrolimus corrected trough level are shown in figures 6 and 7. In figure 6 the data are 
represented according to the donors’ haplotype, with n=23 values for “normal”group in the 
first week and 29 in the second, and for “variant”, 77 in the first week and 93 in the second. 
Figure 7 shows the data arranged according to the haplotype of the recipients, with 21, 19, 86 
and 110 values, respectively. In both figures we find significant differences of p<0,05 between 
the two groups with Mann-Whitney two-tailed test. 
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GENOTYPE 1 
(R/D)* 
Nº 
PATIENTS
Nº 
SAMPLES
GENOTYPE 2 
(R/D)* 
Nº 
PATIENTS
Nº 
SAMPLES 
Δ% 
TT/TT 
4 7 
CC/CC 6 12 141.4 
CT/CT 15 33 94.6 
TT/CC 5 8 44.53 
TT/CT 9 20 71.88 
CC/TT 
1 2 
CC/CC 6 12 286.53 
CC/CT 8 14 196.52 
CT/TT 
2 4 
CT/CC 14 29 107.52 
CT/CT 15 33 71.29 
Table 8. Percent increase (Δ%) of the median in the second week after transplantation, 
comparing different groups according to their genotype recipient/donor, as shown in 
figures 2-5. Columns 2 and 5 show the number of recipients in each group, and columns 3 
and 6 show the number of tacrolimus levels included. *Recipient/Donor. 
 
Fig. 6. Tacrolimus corrected trough concentration in renal recipients regarding SNPs 
rs1045642, rs1128503 and rs2032582 haplotype in their donors. Corrected trough 
concentration (C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding the 
patient’s donor genotype, showing the data from recipients divided in two groups 
according to their donor’s genotype being Normal those whose donors are CC/CC/GG in 
the three SNPs respectively, and Variant those with any of the other possible combinations. 
The results displayed correspond to the first (1w) and second week (2w) after 
transplantation. The horizontal line inside each bar is the median of the data, the bar is the 
interquartilic range, including 50% of the data, and the lines up and down the bars cover the 
whole data range for each set. Significant differences were found between the two groups at 
the first week (p<0,05) employing Mann-Whitney two-tailed test. 
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Fig. 7. Tacrolimus corrected trough concentration in renal recipients regarding SNPs 
rs1045642, rs1128503 and rs2032582 haplotype in the patients. Corrected trough 
concentration (C0/(dose/weight)) (C0: ng/mL; dose: mg/Kg/day; weight: Kg) regarding 
the recipients’ genotype, showing the data from recipients divided in two groups 
according to their haplotype being Normal those CC/CC/GG in the three SNPs 
respectively, and Variant those with any of the other possible combinations. The results 
displayed correspond to the first (1w) and second week (2w) after transplantation. The 
horizontal line inside each bar is the median of the data, the bar is the interquartilic range, 
including 50% of the data, and the lines up and down the bars cover the whole data range 
for each set. Significant differences were found between the two groups at the second 
week (p<0,05) employing Mann-Whitney two-tailed test. 
5.3.2 CYP3A5 
The corresponding data for the analysis of SNPs rs776746 and rs10264272 of CYP3A5 
showed the expected behavior, already described in the literature. In figure 8, we find a 
significant increase in tacrolimus concentration in patients GG, the non-expressors, 
regarding GA. We failed to have AA patients, which we would expect to have even lower 
concentrations than GA. Regarding SNP rs102642272, we only had one GA patient, so we 
could not perform any statistical analysis, however the only three values that we have 
from that recipient are consistent with the expected results of higher tacrolimus 
concentrations. 
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Fig. 8. Tacrolimus corrected trough concentration in renal recipients regarding SNP rs776746 
genotype. Tacrolimus corrected trough concentration (C0/Dc (dose/weight)) (C0 ng/mL; 
dose mg/Kg/24 hours; weight Kg) is shown regarding recipient’s genotype GG or GA, in 
the first (1w) and second (2w) week after transplantation. P<0,05 statistically significant 
difference was found between groups at both weeks by Mann-Whitney one-tailed test. 
 
Fig 9. Tacrolimus corrected trough concentration in renal recipients regarding SNP 
rs10264272 genotype. Tacrolimus corrected trough concentration (C0/Dc (dose/weight)) (C0 
ng/mL; dose mg/Kg/24 hours; weight Kg) is shown regarding recipient’s genotype GG or 
GA, in the first (1w) and second (2w) week after transplantation. No statistical difference 
was found between groups. 
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6. Conclusions 
The importance of obtaining the best results in terms of efficacy and safety, but also in terms 
of economic saving is out of discussion. With the personalized medicine we search for 
formulas that help us decide wich is the perfect treatment in drug and dose for each patient. 
This is actually possible nowadays with the help of tools as pharmacogenetics, but there is 
still a lot of work to do before this tool would really be useful in all the therapeutic areas in 
the daily work with the patient. There are a lot of published works about many genes and 
SNPs, but when we look deeply for the usefulness, not all of them pass the test. In this work 
we have confirmed with real patients’ data, the expected effect of five different SNPs in 
ABCB1 and CYP3A5 genes. We have also demonstrated that there is an additional effect of 
the donor’s genotype translated into the received organ, which is also playing a role in the 
transport (ABCB1) of tacrolimus (Herrero et al., 2010).  
But there are still many other genes related to tacrolimus, and also to other 
immunosuppressants as cyclosporine and micophenolic acid, which have to be explored 
and validated in the real clinical setting. 
Interdisciplinar groups are also necessary for a complete approach to the scenario, only 
summing the work of different professionals could we achieve the success. The results in 
other kinds of transplantation must also be taken in consideration (Jordán et al, 2011). 
The effects of many other factors need also to be considered, as they may overlap or disguise 
a genotype effect. 
With the data in our hands, we have found a clear effect of increased tacrolimus trough 
concentration associated with TT genotype in SNPs rs1045642, rs1128503 and rs2032582 in 
ABCB1 gene. And regarding CYP3A5, we have also found an increase of the mentioned 
levels in the non-expressor genotype GG. These data, in agreement with more published 
works by other groups (Haufroid et al. 2006, Thervet et al., 2010), makes us consider 
conducting an analysis to any patient before initiating an immunosuppressive therapy, 
before the transplantation is performed in order to know in advance the optimal dose based 
on the polymorphisms found.  
Further studies with a higher number of patients, also in long term responses, relating 
several SNPs at the same time, building haplotypes and taking also into consideration the 
correlation with adverse effects are required to establish this “new” and promising 
Pharmacogenetic Tool.  
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